David T Hung

US Patent:

6494859, Dec 17, 2002

Filed:

Apr 28, 1999

Appl. No.:

09/301058

Inventors:

Susan M. Love - Pacific Palisades CA
David Hung - Belmont CA
Xuanmin He - Palo Alto CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61M 100

US Classification:

604 28, 604 19, 604 27, 604 48, 604 73, 604 74, 604 75, 604 76

Abstract:

Methods, kits, and apparatus for obtaining cellular, chemical, and other materials from breast ducts are described. A single milk duct is accessed and washed with a washing fluid to obtain marker materials from the lining the duct. The washing fluid is then collected, and the marker materials in the washing fluid identified and analyzed. Usually, the washing fluid is introduced using a syringe through a lumen of a dual-lumen catheter. The ductal volume is filled with the washing fluid and excess fluid flows outwardly through a second lumen of the dual-lumen catheter, from which it is collected. Methods and kits provide for collection of fluid and cells by a lavage procedure that includes applying external pressure to the breast to improve the yield of fluid and cells from the breast duct.

US Patent:

6642010, Nov 4, 2003

Filed:

Feb 10, 2000

Appl. No.:

09/502404

Inventors:

Susan Love - Pacific Palisades CA
David Hung - Belmont CA
Hui Cen - Oakland CA

Assignee:

Cytyc Health Corporation - Boxborough MA

International Classification:

G01N 33574

US Classification:

435 723, 435 71, 435 721

Abstract:

The invention is to methods for screening women for breast cancer and precancer by determining a level of an estrogen-related marker. The invention further provides methods of treating such patients identified as having one or more abnormal ductal epithelial cells and an estrogen-related marker. The invention provides methods for screening patient for hormone replacement therapy (HRT), and of monitoring such patients once they begin HRT. The invention provides methods of treating peri-, menopausal or postmenopausal women for both cancer risk reduction and menopausal symptoms (or other conditions related to lowered systemic estrogen levels). The invention also provides kits for the screening, monitoring, and treating methods described.

US Patent:

20030039959, Feb 27, 2003

Filed:

Oct 1, 1999

Appl. No.:

09/410336

Inventors:

SUSAN LOVE - PACIFIC PALISADES CA, US
JULIAN NIKOLCHEV - PORTOLA VALLEY CA, US
DAVID HUNG - BELMONT CA, US

International Classification:

C12Q001/68
G01N033/574

US Classification:

435/006000, 435/007230

Abstract:

The invention provides methods of identifying premalignant and malignant breast cancer, determining lymph node involvement in patients diagnosed with premalignant and malignant breast cancer growths, and methods of treating premalignant and malignant breast cancer. The diagnostic and methods comprise intraductal administration of a targeting molecule either alone acting as an identifying agent, or coupled to an identifying agent; the therapeutic methods comprise intraductal administration of a targeting molecule coupled to a therapeutic agent or administration of a targeting molecule having therapeutic activity in and of itself.

US Patent:

20030049262, Mar 13, 2003

Filed:

May 5, 2000

Appl. No.:

09/565642

Inventors:

Susan Love - Pacific Palisades CA, US
Julian Nikolchev - Portola Valley CA, US
David Hung - Belmont CA, US
Hui Cen - Oakland CA, US

International Classification:

G01N033/574
A61K039/395
C12Q001/68
C07H021/04

US Classification:

424/155100, 435/006000, 435/007230

Abstract:

The disclosure describes methods of identifying and treating premalignant and malignant breast cancer, and systems and kits for the same. The diagnostic methods comprise intraductal administration of agents that can clear in the body comprising a targeting molecule either alone acting as an identifying agent, or coupled to an identifying agent; the therapeutic methods comprise intraductal administration of agents that can clear n the body comprising a targeting molecule coupled to a therapeutic agent or a targeting molecule having also therapeutic activity.

US Patent:

20040029202, Feb 12, 2004

Filed:

Aug 11, 2003

Appl. No.:

10/637545

Inventors:

Susan Love - Pacific Palisades CA, US
David Hung - Belmont CA, US
Hui Cen - Oakland CA, US

Assignee:

Cytyc Health Corporation - Boxborough MA

International Classification:

G01N033/574
C12Q001/26

US Classification:

435/007230, 435/025000

Abstract:

The invention is to methods for screening women for breast cancer and precancer by determining a level of an estrogen-related marker. The invention further provides methods of treating such patients identified as having one or more abnormal ductal epithelial cells and an estrogen-related marker. The invention provides methods for screening patient for hormone replacement therapy (HRT), and of monitoring such patients once they begin HRT. The invention provides methods of treating peri-, menopausal or postmenopausal women for both cancer risk reduction and menopausal symptoms (or other conditions related to lowered systemic estrogen levels). The invention also provides kits for the screening, monitoring, and treating methods described.

US Patent:

20040224347, Nov 11, 2004

Filed:

Jun 1, 2004

Appl. No.:

10/858086

Inventors:

Susan Love - Pacific Palisades CA, US
Julian Nikolchev - Portola Valley CA, US
David Hung - Belmont CA, US
Hui Cen - Oakland CA, US

Assignee:

CYTYC CORPORATION - Boxborough MA

International Classification:

C12Q001/68
G01N033/574
C07H021/04

US Classification:

435/006000, 435/007230

Abstract:

The invention provides methods of identifying premalignant and malignant breast cancer, determining lymph node involvement in patients diagnosed with premalignant and malignant breast cancer growths, and methods of treating premalignant and malignant breast cancer. The diagnostic and methods comprise intraductal administration of a targeting molecule either alone acting as an identifying agent, or coupled to an identifying agent; the therapeutic methods comprise intraductal administration of a targeting molecule coupled to a therapeutic agent or administration of a targeting molecule having therapeutic activity in and of itself.

US Patent:

20070161063, Jul 12, 2007

Filed:

Mar 2, 2007

Appl. No.:

11/713495

Inventors:

Susan Love - Pacific Palisades CA, US
David Hung - Belmont CA, US
Hui Cen - Oakland CA, US

International Classification:

G01N 33/574

US Classification:

435007230

Abstract:

The invention is to methods for screening women for breast cancer and precancer by determining a level of an estrogen-related marker. The invention further provides methods of treating such patients identified as having one or more abnormal ductal epithelial cells and an estrogen-related marker. The invention provides methods for screening patient for hormone replacement therapy (HRT), and of monitoring such patients once they begin HRT. The invention provides methods of treating peri-, menopausal or postmenopausal women for both cancer risk reduction and menopausal symptoms (or other conditions related to lowered systemic estrogen levels). The invention also provides kits for the screening, monitoring, and treating methods described.

US Patent:

20070218056, Sep 20, 2007

Filed:

Feb 12, 2007

Appl. No.:

11/705277

Inventors:

Susan Love - Pacific Palisades CA, US
Julian Nikolchev - Portola Valley CA, US
David Hung - Belmont CA, US

International Classification:

A61K 39/395

US Classification:

424138100

Abstract:

The invention provides methods of identifying premalignant and malignant breast cancer, determining lymph node involvement in patients diagnosed with premalignant and malignant breast cancer growths, and methods of treating premalignant and malignant breast cancer. The diagnostic and methods comprise intraductal administration of a targeting molecule either alone acting as an identifying agent, or coupled to an identifying agent; the therapeutic methods comprise intraductal administration of a targeting molecule coupled to a therapeutic agent or administration of a targeting molecule having therapeutic activity in and of itself.